Product
Supplier
Encyclopedia
Inquiry
ARA290 (Cibinetide) buy - large image1
ARA290 (Cibinetide) buy - image1
ARA290 (Cibinetide) buy - image2
ARA290 (Cibinetide) buy - image3
ARA290 (Cibinetide) buy - image4
ARA290 (Cibinetide) buy - image5
ARA290 (Cibinetide) buy - image6

ARA290 (Cibinetide)

TDS 20 Inquiries

Unit Price:

$75/UNIT FOB

Get Latest Price
CAS No.:

1208243-50-8

Grade:

Pharmaceutical Grade

Content:

98%

Port:

Guangzhou

Brand:

Guangsheng

Packaging:

10-16mg*10vials

Price valid (until):

2030-06-18

Company Type:
Trader
Location:
China
Qualification:
Main Products:

beaty prodt

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Name:  Lynn
    Wechat:  15914422644

    Tel:+86  15914422644

    Whatsapp: +852 6252 8290

    Email:    guangsheng 5   @zgguangsheng.com

    1. Core Molecular & Physical Traits

    Item Details
    Full Name Pyroglutamate Helix B Surface Peptide (PHBSP), Cibinetide (ARA290)
    Amino Acid Sequence 11 amino acids (pGlu‑Glu‑Gln‑Leu‑Glu‑Arg‑Ala‑Leu‑Asn‑Ser‑Ser)
    Molecular Weight 1257.32 Da (C₅₁H₈₄N₁₆O₂₁)
    CAS No. 1208243-50-8 (free base)
    Purity ≥98% (HPLC), endotoxin < 0.01 EU/μg (research grade)
    Formulation Lyophilized acetate salt; reconstitute with sterile water/buffer for subcutaneous/intraperitoneal injection
    Pharmacokinetics Half‑life: 2–4 hours (human); low immunogenicity, rapid tissue distribution

    2. Mechanism of Action

    ARA290 selectively binds to the innate repair receptor (IRR)—a heteromer of erythropoietin receptor (EPOR) and β‑common receptor (CD131)—avoiding EPOR homodimers that drive erythropoiesis. Key signaling pathways activated:
    1. JAK2/STAT5: Suppresses pro‑inflammatory cytokines (TNF‑α, IL‑1β) and reduces oxidative stress.
    2. PI3K/Akt: Inhibits apoptosis, enhances cell survival, and promotes small nerve fiber regeneration.
    3. MAPK/ERK: Boosts tissue repair, angiogenesis, and wound healing.
    Its receptor selectivity eliminates erythropoietic side effects of native EPO, focusing on tissue protection and repair.

    3. Key Biological Effects & Research Applications

    Core Effects (Preclinical & Clinical)

    • Neuroprotection/Regeneration: Promotes small nerve fiber regrowth, reduces neuropathic pain (diabetic/sarcoidosis‑related), and improves corneal nerve density.
    • Anti‑Inflammatory: Attenuates pro‑inflammatory mediator expression, mitigating organ damage from ischemia‑reperfusion and autoimmune conditions.
    • Organ Protection: Preserves renal, myocardial, retinal, and pancreatic islet function in injury/disease models.
    • Wound Healing: Accelerates closure of dermal ulcers and biopsy wounds.
    • Metabolic Support: Improves insulin sensitivity and protects against high glucose‑induced cell damage.

    Research & Clinical Focus Areas

    Area Applications
    Neuropathy Diabetic neuropathy, small fiber neuropathy, traumatic brain injury (TBI)
    Inflammatory Diseases Sarcoidosis, autoimmune disorders, ischemic organ injury
    Organ Transplantation Pancreatic islet protection and engraftment enhancement
    Metabolic Disorders Insulin resistance, diabetic retinopathy
    Wound Care Decubitus ulcers, dermal injury repair

    4. Dosing & Administration (Research/Clinical)

    Model/Setting Route Dose Range Frequency Cycle
    Rodents IP/SC 0.8–8 nmol/kg (renal injury); 30 μg/kg (TBI) Daily 2–4 weeks
    Humans (Clinical) SC 2–4 mg Once daily/every other day 4–12 weeks (neuropathy trials)

    Note: Higher doses may increase injection site reactions; dose adjustment for renal/hepatic impairment is recommended.

    5. Safety & Precautions

    Common Side Effects (Clinical)

    • Mild injection site erythema/edema.
    • Transient fatigue or headache (rare, dose‑related).
    • No significant erythropoiesis stimulation or hypertension (vs. EPO).

    Critical Warnings

    • For research/clinical development only; not approved for human therapeutic use outside trials.
    • Store at -20°C; reconstituted solution stable for 72 hours at 2–8°C.
    • Avoid use in patients with hypersensitivity to peptide components.


      About Us 


    Shop High purity Cortagen-Detailed Image 1
    Shop High purity Cortagen-Detailed Image 2
    Shop High purity Cortagen-Detailed Image 3
    Shop High purity Cortagen-Detailed Image 4
    Shop High purity Cortagen-Detailed Image 5

    Certificates

    Basic Info
    Product Name:

    Cibinetide

    Other Name:

    ARA-290 (Cibinetide);ARA290, >98%;ARA290,Cibinetide, >98%;ARA290;WZTIQQBMSJTRBR-MUZUOSMHSA-N;ara290/Poziotinib;L-Serine, 5-oxo-L-prolyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-α-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-;ARA-290(Cibinetide) acetate

    CAS No.:

    1208243-50-8

    Molecular Formula:

    C51H84N16O21

    InChIKeys:

    WZTIQQBMSJTRBR-WYKNNRPVSA-N

    Molecular Weight:

    1257.31

    EC Number:

    200-001-8

    Color/Form:

    White to off-white

    Categories:

    Other Chemical Drugs

    Characteristics
    Density:

    1.56±0.1 g/cm3(Predicted)

    PKA:

    2.90±0.10(Predicted)

  • Seller Information
    Business Type:

    Trader

    Main Products:

    beaty prodt

    Location:

    Yongtai Jinli City Plaza, Baiyun District, Guangzhou City, Guangdong Province

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    30

    Total Annual Revenue:

    Less than $1 million

    Total Employees:

    5-10

    Year of Establishment:

    2023

  • Inquiry History
    20 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Factory Supply 99% Purity Ara 290 Peptides Raw Lyophilized Powder CAS 1208243-50-8

    1 G Oct 29, 2023
    United States

    ARA 290

    1 G Apr 13, 2026
    United States

    ARA-290 Peptide

    1 G Feb 6, 2026
    United States

    ARA-290

    10 PCS Nov 15, 2025
    Thailand

    Cibinetide

    200 KG May 10, 2025
    Lithuania

    ARA 290

    60  Nov 28, 2023
    United States

    ARA-290 10mg

    100 PCS Apr 17, 2026
    United States

    ARA-290

    10 MT May 10, 2024
    Denmark

    Cibinetide

    5 G Feb 11, 2024
    Lithuania

    ARA 290

    10  Nov 28, 2023
    United States

    ARA 290

    1 KG Jun 15, 2026
    Belgium

    ARA290

    1 KG May 20, 2026
    United States

    Reta

    60  May 4, 2026
    United States

    ARA-290 Lyophilized

    800 MG Apr 17, 2026
    United States

    Ara290

    1 G Apr 17, 2026
    Nigeria

    Snap 8

    100 PCS Apr 10, 2026
    United States

    Ara 290

    1 G Apr 8, 2026
    United States

    ARA-290

    1 G Apr 5, 2026
    Bulgaria

    ARA-290 98%

    5 KG Jun 5, 2025
    Denmark

    Cibinetide

    5 G Feb 10, 2024
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.